Research programme: porphyrin-based cancer therapeutics - OncoSelect Therapeutics

Drug Profile

Research programme: porphyrin-based cancer therapeutics - OncoSelect Therapeutics

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator OncoSelect Therapeutics
  • Developer OncoSelect Therapeutics; University of Texas Health Science Center at San Antonio
  • Class Porphyrins
  • Mechanism of Action Image enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 23 Jun 2016 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top